4.4 Article

Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria

期刊

ARTHRITIS CARE & RESEARCH
卷 73, 期 10, 页码 1490-1501

出版社

WILEY
DOI: 10.1002/acr.24520

关键词

-

向作者/读者索取更多资源

An international initiative is underway to develop new classification criteria for identifying patients with antiphospholipid syndrome, resulting in 27 candidate criteria organized into 6 clinical or laboratory domains using evidence- and consensus-based methodology.
Objective An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence- and consensus-based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains. Methods During phase I, the APS classification criteria steering committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains. Results Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in phase II, we initially reduced these items to 64 potential candidate criteria organized into 10 clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into 6 additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification. Conclusion Using data- and consensus-driven methodology, we identified 27 APS candidate criteria in 6 clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real-world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports

Michelle Petri, Helain Landy, Megan E. B. Clowse, Kim Gemzoe, Munther Khamashta, Milena Kurtinecz, Roger A. Levy, Andrew Liu, Rebecca Marino, Paige Meizlik, Jeanne M. Pimenta, Kelsey Sumner, Hugh Tilson, Mary Beth Connolly, Keele Wurst, Julia Harris, Holly Quasny, Patricia Juliao, David A. Roth

Summary: This study describes the available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab. The results show that there is a risk of birth defects in belimumab-exposed pregnancies, although no consistent pattern of birth defects was observed across different datasets. Additionally, a higher proportion of belimumab-exposed women experienced pregnancy loss. However, due to the limited number of exposed pregnancies, confounding factors, and incomplete data, no clear recommendations can be made regarding the risk of birth defects and pregnancy loss with belimumab use.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Hematology

Circulating Endothelial Cells are Associated with Thromboembolic Events in Patients with Antiphospholipid Antibodies

Thomas Foret, Virginie Dufrost, Marie Heymonet, Jessie Risse, Gilbert C. Faure, Huguette Louis, Jeremy Lagrange, Patrick Lacolley, Katrien Devreese, Sebastien Gibot, Veronique Regnault, Stephane Zuily, Denis Wahl

Summary: This study demonstrated that the levels of circulating endothelial cells (CECs) were associated with thromboembolic events in patients with antiphospholipid antibody (aPL) and/or autoimmune diseases.

THROMBOSIS AND HAEMOSTASIS (2023)

Article Veterinary Sciences

Qualitative risk assessment of homogeneity, stability, and residual concentrations of antimicrobials in medicated feed and drinking water in pig rearing

Despoina Georgaki, Femke Vandael, Helena Cardoso de Carvalho Ferreira, Maria Eleni Filippitzi, Patrick De Backer, Mathias Devreese, Jeroen Dewulf, Siska Croubels

Summary: This study conducted a qualitative risk assessment to estimate the risks associated with reduced homogeneity and stability, as well as increased residual concentrations of antimicrobial drugs in medicated feed and drinking water on pig farms. Factors such as human error during the preparation of medicated feed and dosing pump type for medicated drinking water were found to pose moderate to high risks. It is crucial to identify and understand these factors in order to ensure the effectiveness and safety of antimicrobial drug treatment.

BMC VETERINARY RESEARCH (2023)

Article Medicine, General & Internal

Patterns and factors associated with pneumococcal vaccination in a prospective cohort of 1,697 patients with rheumatoid arthritis

Konstantinos Thomas, Argyro Lazarini, Evripidis Kaltsonoudis, Paraskevi V. Voulgari, Alexandros A. Drosos, Argyro Repa, Ainour Molla Ismail Sali, Prodromos Sidiropoulos, Panagiota Tsatsani, Sousana Gazi, Kalliopi Fragkiadaki, Maria G. Tektonidou, Petros P. Sfikakis, Pelagia Katsimbri, Dimitrios Boumpas, Evangelia Argyriou, Kyriaki A. Boki, Konstantina Karagianni, Christina Katsiari, Gerasimos Evangelatos, Alexios Iliopoulos, Eleftheria P. Grika, Panagiotis G. Vlachoyiannopoulos, Theodoros Dimitroulas, Alexandros Garyfallos, Konstantinos Melissaropoulos, Panagiotis Georgiou, Constantinos Georganas, Periklis Vounotrypidis, Konstantinos Ntelis, Maria Areti, George D. Kitas, Dimitrios Vassilopoulos

Summary: The rate of pneumococcal vaccination among rheumatoid arthritis (RA) patients remains suboptimal, with 40% remaining unvaccinated. Severe disease, bDMARD use, comorbidities, and influenza vaccination were significant factors associated with pneumococcal vaccination, highlighting the need for cultivating a vaccination culture in RA patients.

FRONTIERS IN MEDICINE (2023)

Article Immunology

Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases

Laura Andreoli, Cecilia B. Chighizola, Luca Iaccarino, Angela Botta, Maria Gerosa, Veronique Ramoni, Chiara Tani, Bonnie Bermas, Antonio Brucato, Jill Buyon, Irene Cetin, Christina D. Chambers, Megan E. B. Clowse, Nathalie Costedoat-Chalumeau, Maurizio Cutolo, Sara De Carolis, Radboud Dolhain, Elisa M. Fazzi, Frauke Foerger, Ian Giles, Isabell Haase, Munther Khamashta, Roger A. Levy, Pier Luigi Meroni, Marta Mosca, Catherine Nelson-Piercy, Luigi Raio, Jane Salmon, Peter Villiger, Marie Wahren-Herlenius, Marianne Wallenius, Cristina Zanardini, Yehuda Shoenfeld, Angela Tincani

Summary: Autoimmune rheumatic diseases (ARD) pose challenges to reproductive health. Preconception counseling should consider factors such as fertility, disease impact on pregnancy outcomes, disease activity during pregnancy, medication compatibility, and biomarkers predictive of adverse pregnancy outcomes (APO). Diseases like preeclampsia and pregnancy-induced hypertension are more likely to occur in women with ARD. Placental insufficiency can result in restricted fetal growth. Treatment with compatible drugs is essential for maternal and fetal wellbeing. While limited data is available on medication usage during pregnancy, TNF inhibitors are recommended. Non-medical issues like sexual dysfunction and long-term outcomes of children also require attention in this review. Collaborative research and pregnancy registries will contribute to future insights.

AUTOIMMUNITY REVIEWS (2023)

Article Rheumatology

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks

Binod Neupane, Pragya Shukla, Mahmoud Slim, Amber Martin, Michelle Petri, George K. Bertsias, Alfred H. J. Kim, Antonis Fanouriakis, Roger A. Levy, Deven Chauhan, Nick Ballew

Summary: This study aimed to compare the efficacy of belimumab and anifrolumab in SLE patients for informed treatment practices. The results showed that belimumab and anifrolumab had similar efficacy in SLE patients, but the uncertainty around the point estimate means we cannot rule out the possibility of clinically meaningful benefit for either treatment. Further research is needed to identify which patient groups may benefit more from anifrolumab or belimumab.

LUPUS SCIENCE & MEDICINE (2023)

Article Rheumatology

Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease

Alexandros Panagiotopoulos, Christos Koutsianas, Nikolaos Kougkas, Dimitra Moschou, Vasiliki-Kalliopi Bournia, Sousana Gazi, Maria G. Tektonidou, Dimitrios Vassilopoulos, Petros P. Sfikakis, George E. Fragoulis

Summary: This study reports the efficacy of switching to ixekizumab (IXE) after inadequate response to another interleukin-17 (IL-17) inhibitor (SEC) in psoriatic arthritis (PsA) patients. The results showed improvements in peripheral arthritis and skin involvement, as well as significant improvements in axial disease in patients with PsA. These findings suggest that IXE is effective in treating PsA patients, including those with axial disease, in a real-world setting.

RHEUMATOLOGY INTERNATIONAL (2023)

Meeting Abstract Hematology

EVALUATION OF TWO ASSAYS FOR MONITORING EMICIZUMAB AND A THROMBIN GENERATION ASSAY IN PATIENTS WITH HEMOPHILIA A

Arne Vandevelde, Luna Crevits, Katrien M. J. Devreese

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

Meeting Abstract Hematology

STABILITY OF ANTI-FACTOR XA ACTIVITY AFTER SAMPLE STORAGE

Pauline Vermeiren, Arne Vandevelde, Katrien M. J. Devreese

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

Meeting Abstract Hematology

HEPARIN-CALIBRATED CHROMOGENIC ANTI-XA ASSAY FOR THE DETECTION OF THRESHOLD-LEVELS OF DIRECT ORAL ANTICOAGULANTS (DOAC)

Delphine De Smet, Dimitri Hemelsoet, Katrien Devreese

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

Article Rheumatology

Lupus spectrum ambiguity has long-term negative implications for patients

Ian N. Bruce, Joy Buie, Lauren Bloch, Sang-Cheol Bae, Karen Costenbader, Roger A. Levy, Victoria P. Werth, Ashley Marion, Sanjyot Sangodkar, Susan Manzi

Summary: Lupus, a complex disease, poses challenges in diagnosis due to non-specific symptoms and a lack of diagnostic criteria and referral pathways. To address these issues, virtual meetings were held with experts in lupus care, including physicians, treatment developers, and patient advocacy group representatives. The discussions highlighted the need for a clearer understanding of lupus, advancements in biotechnology, and potential development of a lupus spectrum to support timely and accurate diagnosis.

LUPUS SCIENCE & MEDICINE (2023)

Article Rheumatology

16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends

Tatsuya Atsumi, Cecilia B. Chighizola, Yuichiro Fujieda, Ian Mackie, Massimo Radin, Robert Roubey, Maria Laura Bertolaccini

Summary: Classification criteria for antiphospholipid syndrome (APS) require specific antibodies to satisfy the laboratory disease definition, but there have been additional antibodies proposed in recent years. This article evaluates these new antibodies through the study and discussion of relevant data, and also discusses the testing of LA and the value of triple positivity.
Article Rheumatology

Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression

Lorena Rodriguez-Martinez, Cristina Garcia-Moreno, Eva Perez-Pampin, Maria J. Gomara, Juan C. Sarmiento-Monroy, Yolanda Lopez-Golan, Jose A. Gomez-Puerta, Antonio Mera-Varela, Carmen Conde, Raimon Sanmarti, Isabel Haro, Antonio Gonzalez

Summary: Autoantibodies play a critical role in the pathogenesis and clinical assessment of rheumatoid arthritis. The anti-malondialdehyde-acetaldehyde (anti-MAA) antibodies have been claimed to have high sensitivity for all rheumatoid arthritis patients. However, the sensitivity of anti-MAA antibodies varies significantly between patient collections and is determined by complex factors including ethnicity, smoking, and sex.

ARTHRITIS RESEARCH & THERAPY (2023)

Article Hematology

Added value of antiphosphatidylserine/prothrombin antibodies in the workup of obstetric antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

Arne Vandevelde, Jean-Christophe Gris, Gary W. Moore, Jacek Musial, Stephane Zuily, Denis Wahl, Katrien M. J. Devreese

Summary: Currently, the added value of antiphosphatidylserine/prothrombin antibodies testing in the diagnosis of obstetric antiphospholipid syndrome seems limited compared with other antibodies. However, it may be useful in specific subsets of patients.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Letter Health Care Sciences & Services

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Nick Ballew, Aneela Mian, Roger Abramino Levy, Matt Bradley

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2023)

暂无数据